文献速递胸部肿瘤

新辅助度伐利尤单抗联合化疗后辅助度伐利尤单抗治疗可切除非小细胞肺癌的手术结局

Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
PubMed 文献 · J Thorac Oncol · 2025-06-20

AEGEAN研究评估围手术期度伐利尤单抗联合新辅助化疗对比单纯新辅助化疗治疗可切除非小细胞肺癌的手术结局。两组分别有80.6%和80.7%的患者接受手术,R0切除率度伐利尤单抗组为94.7%、安慰剂组为91.3%,手术并发症比例相似(59.1%对60.1%)。结论认为加用度伐利尤单抗对手术可行性、方式、类型或时机无不利影响,手术安全性可耐受。

要点

  • 度伐利尤单抗组与安慰剂组手术率分别为80.6%和80.7%,完成手术率分别为77.6%和76.7%。
  • R0切除率度伐利尤单抗组94.7%对安慰剂组91.3%,数值上更高但为描述性统计。
  • 手术并发症比例两组相似(59.1%对60.1%),主要为1级或2级(53.0%对51.8%)。

核心结论

  • 在新辅助化疗基础上加用度伐利尤单抗对手术可行性、手术方式、手术类型或手术时机无不利影响,且手术安全性可耐受。

研究设计与样本

  • AEGEAN研究的手术结局分析,纳入初治可切除非小细胞肺癌(II-IIIB期[N2])、ECOG体能状态0或1的患者,按1:1随机接受铂类化疗联合度伐利尤单抗或安慰剂静脉给药(每3周,4周期)后手术,术后接受度伐利尤单抗或安慰剂(每4周,12周期)。
  • 手术结局在改良意向治疗(mITT)人群中采用描述性统计进行总结,mITT人群排除了已知EGFR或ALK异常的患者。

主要发现

  • mITT人群740例中737例接受治疗,度伐利尤单抗组366例、安慰剂组371例;两组分别有80.6%和80.7%接受手术、77.6%和76.7%完成手术。
  • 在接受手术的295例和302例患者中,分别有17.3%和22.2%手术延迟;从末次新辅助给药至手术的中位时间两组均为34.0天。
  • 接受手术的患者中,开放手术比例分别为49.2%和50.7%,微创手术比例分别为49.2%和47.0%,肺叶切除术为最常见术式(88.1%对85.4%)。
  • R0切除率度伐利尤单抗组为94.7%、安慰剂组为91.3%,数值上更高;从手术至首次辅助治疗的中位时间分别为50.0天和52.0天。
  • 探索性分析中,基线N2患者降期至N0的比例度伐利尤单抗组47.3%对安慰剂组40.2%,基线N1患者降期至N0的比例53.6%对46.2%;手术并发症比例相似(59.1%对60.1%),主要为1级或2级(53.0%对51.8%,改良安全性分析集)。

关键数值与推荐

  • AEGEAN研究主要终点:围手术期度伐利尤单抗联合新辅助化疗对比单纯新辅助化疗显著改善无事件生存(p = 0.004)和病理完全缓解(p < 0.001),基于mITT人群。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 手术结局采用描述性统计总结,未报告组间统计学比较。
  • 探索性分析中的降期比例仅为数值上更高,原文未报告统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (p = 0.004) and pathologic complete response (p < 0.001; primary end points; modified intention-to-treat [mITT] population, which excluded patients with known EGFR or ALK aberrations) with a manageable safety profile in patients with resectable (R)-NSCLC. Here, we report surgical outcomes from AEGEAN. METHODS: Patients with treatment-naive R-NSCLC (stage II-IIIB [N2]) and Eastern Cooperative Oncology Group performance status 0 or 1 were randomized (1:1) to platinum-based chemotherapy plus durvalumab or placebo intravenously (every 3 wk, 4 cycles) before surgery, followed by durvalumab or placebo (every 4 wk, 12 cycles). Surgical outcomes were summarized for the mITT population using descriptive statistics. RESULTS: A total of 737 out of 740 mITT patients received treatment, 366 and 371 in the durvalumab and placebo arms, respectively; 80.6% and 80.7% underwent surgery, 77.6% and 76.7% completed surgery, and of the 295 and 302 patients who underwent surgery, 17.3% and 22.2% had delayed surgery. The median time from last neoadjuvant dose to surgery was 34.0 days in both arms. Of the patients who underwent surgery, similar proportions had open (49.2% versus 50.7%) and minimally invasive (49.2% versus 47.0%) procedures; lobectomy was the most common procedure (88.1% versus 85.4%). R0 resection rates were numerically higher in the durvalumab versus placebo arm (94.7% versus 91.3%). The median time from surgery to first adjuvant dose was 50.0 versus 52.0 days. In exploratory analyses, a numerically higher proportion of patients in the durvalumab versus placebo arm with baseline N2 nodal status had downstaging from N2 to N0 (47.3% versus 40.2%) or, with baseline N1 nodal status, from N1 to N0 (53.6% versus 46.2%) after surgery. Similar proportions had surgical complication(s) (59.1% versus 60.1%), primarily grade 1 or 2 (53.0% versus 51.8%, modified safety analysis set). CONCLUSION: The addition of durvalumab to neoadjuvant chemotherapy had no detrimental effect on the feasibility, approach, type, or timing of surgery and was associated with a tolerable surgical safety profile, versus neoadjuvant chemotherapy alone. CLINICAL TRIAL INFORMATION: ClinicalTrials.Gov Identifier: NCT03800134.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Mitsudomi T, Heymach JV, Reck M, et al. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC. J Thorac Oncol. 2025. PMID: 40545237. doi:10.1016/j.jtho.2025.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。